{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:14:55Z","timestamp":1794899695444,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Tacrolimus trough concentrations (mean\/variability), as well as concentration-to-dose ratio (C\/D ratio), affect kidney allograft outcomes. We investigated the link between the C\/D ratio and death-censored kidney graft survival (DCGS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We performed a retrospective study on 1029 kidney transplant patients (2004\u20132016) with the following criteria: tacrolimus-based immunosuppression, &gt;1-year graft survival, no initial use of everolimus, and available anti\u2013human leukocyte antigen antibody data. We analyzed the impact of the time-varying C\/D ratio on DCGS. Fast metabolizers were defined by a C\/D ratio &lt; 1.05. We also investigated the effect of an early (mo 3 to mo 6 post transplantation) C\/D ratio below 1.05. Cox survival analyses were performed, adjusting for potential confounders (tacrolimus trough, variability of tacrolimus trough, de novo donor-specific antibody development, cytochrome P450 3A5 genotype, pregraft sensitization, mo 3 glomerular filtration rate).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Time-varying C\/D ratio was significantly associated with DCGS (hazard ratio [HR], 2.35;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) in a univariate model, on the full analysis set comprising 1029 patients. In the multivariate time-varying model, based on 666 patients with available cytochrome P450 3A5 genotypes, the effect of the C\/D ratio remained significant (HR, 2.26;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015); even when glomerular filtration rate at month 3 &lt; 30 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (HR, 2.61;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011), de novo donor-specific antibody development (HR, 4.09;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and continued steroid prescription (HR=2.08,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014) were taken into account (other covariates, including tacrolimus trough concentrations, were nonsignificant). In the same multivariate model, the effect of early C\/D ratio (median at mo 3 and mo 6) remained significantly associated with DCGS (HR, 2.25;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.041).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>C\/D ratio is an independent and early predictor of DCGS. Identification of fast metabolizers could be a strategy to improve graft survival, for example, by optimizing tacrolimus formulation. Mechanistic studies to understand the C\/D ratio effect are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000002920","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T07:33:41Z","timestamp":1565768021000},"page":"1263-1271","source":"Crossref","is-referenced-by-count":70,"title":["The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration\u2013Dose Ratio on Death-censored Graft Survival"],"prefix":"10.1097","volume":"104","author":[{"given":"Thomas","family":"Jouve","sequence":"first","affiliation":[{"name":"Nephrology, Dialysis, Apheresis and Transplantation Department, Grenoble University Hospital, France."},{"name":"Department of Medicine and Pharmacy, Grenoble Alpes University, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Fonrose","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pharmacy, Grenoble Alpes University, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Noble","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis, Apheresis and Transplantation Department, Grenoble University Hospital, France."},{"name":"Department of Medicine and Pharmacy, Grenoble Alpes University, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Janbon","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis, Apheresis and Transplantation Department, Grenoble University Hospital, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Fiard","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pharmacy, Grenoble Alpes University, Grenoble, France."},{"name":"Urology and Transplantation Department, Grenoble University Hospital, France."},{"name":"CNRS\/TIMC-IMAG UMR 5525, Grenoble Alpes University, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Malvezzi","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis, Apheresis and Transplantation Department, Grenoble University Hospital, France."},{"name":"Department of Medicine and Pharmacy, Grenoble Alpes University, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Stanke-Labesque","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pharmacy, Grenoble Alpes University, Grenoble, France."},{"name":"Pharmacology, Pharmacogenetics and Toxicology Laboratory, Grenoble University Hospital, France."},{"name":"INSERM U1042, Grenoble Alpes University, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis, Apheresis and Transplantation Department, Grenoble University Hospital, France."},{"name":"Department of Medicine and Pharmacy, Grenoble Alpes University, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"25","key":"R1-20231002","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"R2-20231002","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the symphony study: observational results 3 years after transplantation.","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"issue":"11","key":"R3-20231002","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/ajt.13946","article-title":"Failure of calcineurin inhibitor (tacrolimus) weaning randomized trial in long-term stable kidney transplant recipients.","volume":"16","author":"Dugast","year":"2016","journal-title":"Am J Transplant"},{"issue":"5","key":"R4-20231002","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study.","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transplant"},{"issue":"8","key":"R5-20231002","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation.","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"R6-20231002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40620-015-0230-0","article-title":"Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.","volume":"29","author":"O\u2019Regan","year":"2016","journal-title":"J Nephrol"},{"issue":"11","key":"R7-20231002","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","article-title":"Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development.","volume":"100","author":"Rodrigo","year":"2016","journal-title":"Transplantation"},{"issue":"11","key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/tri.12806","article-title":"Intrapatient variability in tacrolimus exposure\u2014a useful tool for clinical practice?","volume":"29","author":"Knight","year":"2016","journal-title":"Transpl Int"},{"issue":"10","key":"R9-20231002","doi-asserted-by":"crossref","first-page":"e111128","DOI":"10.1371\/journal.pone.0111128","article-title":"The tacrolimus metabolism rate influences renal function after kidney transplantation.","volume":"9","author":"Th\u00f6lking","year":"2014","journal-title":"PLOS One"},{"issue":"8","key":"R10-20231002","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1097\/TP.0000000000001796","article-title":"High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation.","volume":"101","author":"Egeland","year":"2017","journal-title":"Transplantation"},{"issue":"5","key":"R11-20231002","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/jcm8050587","article-title":"Fast Tac metabolizers at risk\u2014it is time for a C\/D ratio calculation.","volume":"8","author":"Sch\u00fctte-N\u00fctgen","year":"2019","journal-title":"J Clin Med"},{"issue":"3","key":"R12-20231002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/tri.13356","article-title":"High tacrolimus clearance\u2014a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study.","volume":"32","author":"Egeland","year":"2019","journal-title":"Transpl Int"},{"issue":"6","key":"R13-20231002","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int"},{"issue":"4","key":"R14-20231002","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ndt\/gfy128","article-title":"Pitfalls of linear regression for estimating slopes over time and how to avoid them by using linear mixed-effects models.","volume":"34","author":"Janmaat","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"R16-20231002","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/tpj.2014.38","article-title":"Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.","volume":"15","author":"Rojas","year":"2015","journal-title":"Pharmacogenomics J"},{"issue":"Suppl 1","key":"R17-20231002","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/FTD.0000000000000255","article-title":"Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs.","volume":"38","author":"Picard","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"5","key":"R18-20231002","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-018-0717-7","article-title":"Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation.","volume":"58","author":"Tron","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"R19-20231002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients.","volume":"71","author":"Trofe-Clark","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"R20-20231002","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/clinchem\/42.9.1426","article-title":"Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients.","volume":"42","author":"Gonschior","year":"1996","journal-title":"Clin Chem"},{"issue":"5","key":"R21-20231002","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.transproceed.2015.12.133","article-title":"Tacrolimus metabolite M-III may have nephrotoxic and myelotoxic effects and increase the incidence of infections in kidney transplant recipients.","volume":"48","author":"Zegarska","year":"2016","journal-title":"Transplant Proc"},{"issue":"7","key":"R22-20231002","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.transproceed.2018.03.025","article-title":"Evaluation of the relationship between concentrations of tacrolimus metabolites, 13-O-demethyl tacrolimus and 15-O-demethyl tacrolimus, and clinical and biochemical parameters in kidney transplant recipients.","volume":"50","author":"Zegarska","year":"2018","journal-title":"Transplant Proc"},{"issue":"11","key":"R23-20231002","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.118.081935","article-title":"Relationship between in vivo CYP3A4 activity, CYP3A5 genotype, and systemic tacrolimus metabolite\/parent drug ratio in renal transplant recipients and healthy volunteers.","volume":"46","author":"Vanhove","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"R24-20231002","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/14740338.2017.1328051","article-title":"New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.","volume":"16","author":"Jouve","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"R25-20231002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/17512433.2018.1479638","article-title":"Tailoring tacrolimus therapy in kidney transplantation.","volume":"11","author":"Jouve","year":"2018","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T01:02:26Z","timestamp":1696208546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002920","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}